Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2022-09-20 Foreign Filer Report
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
EVUSHELD APPROVED IN EU FOR COVID-19 TREATMENT
Foreign Filer Report
2022-09-20 English
Evusheld approved in EU for COVID-19 treatment
Regulatory Filings Classification · 98% confidence The document begins with 'National Storage Mechanism' and 'RNS Number', indicating it is a regulatory announcement distributed via the London Stock Exchange's RNS service. The content details the EU approval of AstraZeneca's drug Evusheld for COVID-19 treatment, citing clinical trial results (TACKLE Phase III) and providing quotes from management and medical experts. This is a specific corporate announcement regarding regulatory/product news, not a comprehensive annual report (10-K), an earnings release (ER), or a general investor presentation (IP). Since it is a formal, time-sensitive announcement distributed through the RNS system that doesn't fit the other specific categories (like DIRS, DIV, or CT), the most appropriate classification is the general regulatory filing category, RNS.
2022-09-20 English
DANICOPAN PHASE III TRIAL MET PRIMARY ENDPOINT
Foreign Filer Report
2022-09-16 English
NIRSEVIMAB RECOMMENDED FOR APPROVAL IN EU BY CHMP
Foreign Filer Report
2022-09-16 English
EVUSHELD POSITIVE CHMP OPINION IN EU
Foreign Filer Report
2022-09-16 English
Danicopan Phase III trial met primary endpoint
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 7314Z' and includes the date and time stamp typical of a regulatory news service announcement. The content details interim clinical trial results for a drug (Danicopan) and concludes with contact information for Investor Relations and a footer explicitly mentioning 'This information is provided by RNS, the news service of the London Stock Exchange.' This structure strongly indicates a general regulatory news release, which fits the 'Regulatory Filings' (RNS) category, as it is not a full financial report (10-K, IR), a specific management change (MANG), or a dividend notice (DIV). The document length is substantial (over 10,000 characters), suggesting it is the primary announcement itself, not just a brief RPA.
2022-09-16 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.